glp-1 agonist tablets FDA Approved: Orforglipron (Foundayo) — Oral Drug • FDA approved for chronic weight management • Indicated for obesity and overweight with comorbidities • Oral, once-daily GLP-1 receptor • First non-peptide glp 1 tablet uses GLP-1
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
























